ArticleJournal of biological engineering2026
Anti-CD31 antibody preconditioning for enhancement of endothelial cell capture and vascularization: a novel strategy for bioengineering lung scaffolds.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Recellularization of acellular lung scaffolds is a promising technique for the generation of bioengineered lungs. However, at the present time, pre-clinical evaluation of bioengineered lungs shows graft failure likely due to thrombus formation and bleeding from bronchi. This is believed to be due to the impairment of barrier function, incomplete vascular endothelial cell coverage, and limited endothelial cell function. Therefore, efficient recellularization of the vasculature region of the lung scaffold with functional endothelial cells is an important goal. Coating of decellularized tissues, prior to recellularization has shown improved vascular endothelial cell coverage and endothelial cell function. Here, we report the first demonstration of preconditioning decellularized lung vasculature with an anti‑CD31 antibody to enhance re-endothelialization and vascular function in bioengineered lungs. Presence of the anti-CD31 antibody (Ab) coating resulted in enhanced cell adhesion, viability, proliferation and expression of key endothelial cell genes including Claudin-1 (CLDN) and Endothelial Nitric Oxide Synthase (eNOS). Re-endothelialized scaffolds in the anti-CD31 Ab coated group had morphological reconstitution of the pulmonary vasculature and a higher percentage of endothelialized blood vessels. Markedly greater fractions of intravascular Dextran in the anti-CD31 Ab coated group (20.7 ± 2.5% vesus 51.7 ± 2.5%, p = 0.0001) demonstrated reduced vascular endothelium leakage. Importantly, scaffolds in the anti-CD31 Ab coated group showed reduced platelet aggregation, measured via staining and quantification for integrin αIIb, when perfused with whole-blood ex vivo (17.7 ± 3.8% vs. 6.7 ± 1.5%, p = 0.04); and in vivo following a 30 min-left orthotopic left lung transplant in the mouse (14.7 ± 2.5% vs. 4.3 ± 1.5% in the anti-CD31 group (p = 0.004); suggesting reduced thrombus formation. Taken together, our results frame scaffold preconditioning with anti-CD31 Ab as a viable approach towards the generation of vascularized bioengineered lung constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.